Immunopharmacology Flashcards

1
Q

Which of the following drug is used for patients with SLE and RA?
A. Tacrolimus
B. Cyclosporine
C. Hydroxychloroquine
D. Sirolimus

A

C. Hydroxychloroquine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which drug suppresses intracellular antigen processing and loading of peptides into MHC class II by increasing the pH of lysosomal and endosomal compartments?

A

Hydroxychloroquine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Recombinant humanized IgG1 that binds to soluble and membrane-associated IL-6 receptors to inhibit signaling

A

Tocilizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Anti-IgE recombinant humanized monoclonal antibody for allergic asthma in adult and adolescent patients whose symptoms are REFRACTORY TO INHALED CORTICOSTEROIDS

A

Omalizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Total serum IgE levels may remain elevated in patients for up to how long after omalizumab administration?

A

1 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which of the 2 anticytokine-antibodies below is used for Crohn’s disease and RA?
A. Etanercept
B. Infliximab

A

B. Infliximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which of the 2 anticytokine-antibodies can cause reactivation of latent TB?
A. Etanercept
B. Infliximab

A

B. Infliximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which of the 2 anticytokine-antibodies below is used for Psoriatic arthritis and RA?
A. Etanercept
B. Infliximab

A

A. Etanercept

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which of the 2 anticytokine-antibodies is a genetically engineered fusion protein that prevent TNF-α from binding to TNFR1 and TNFR2?
A. Etanercept
B. Infliximab

A

A. Etanercept

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which of the 2 anticytokine-antibodies inhibit T-cell and macrophage function?
A. Etanercept
B. Infliximab

A

B. Infliximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which of the 2 anticytokine-antibodies is a chimeric monoclonal antibody that cross links with membrane bound TNF-α receptors on cell surface?
A. Etanercept
B. Infliximab

A

B. Infliximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which antimetabolite inhibits lymphocyte folate metabolism?

A

Methotrexate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

This antimetabolite suppresses BOTH B and T lymphocytes, including mitogen and mixed lymphocyte responses, probably by DE NOVO SYNTHESIS OF PURINES. The active product inhibits inosine monophosphate dehydrogenase, leading to suppression of T- and B-lymphocyte proliferation.

A

Mycophenolate mofetil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What to do if a patient using allopurinol must take azathioprine?

A

Reduce azathioprine dose to 1/4-1/3 to prevent toxicity

since both are inactivated by xanthine oxidase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cellcept is a selective noncompetitive inhibitor of which enzyme in the de novo pathway of guanine nucleotide synthesis?

A

Cellcept (Mycophenolate mofetil) inhibits Inosine Monophosphate Dehydrogenase or IMPDH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Cellcept is an alternative to cyclosporine or tacrolimus for intolerant patients when it is combined with:

A

Prednisone

Cellcept is Mycophenolate mofetil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

This is the first line drug for preventing or reducing chronic allograft vasculopathy in cardiac transplant recipients due to antiproliferative properties

A

Mycophenolate mofetil (Cellcept)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Which drug, isolated from the mold Penicillum glaucus, inhibits lymphocyte guanosine synthesis to counter refractory rejection in solid organ transplant patients?

A

Mycophenolate mofetil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

mTOR inhibitors are associated with an increased risk for developing which vascular pathology?

A

Hepatic Artery thrombosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

This is a Proliferation Signal Inhibitor that inhibits JAK enzymes that stimulate hematopoiesis and immune cell function in response to cytokine or growth factor signaling. It is a targeted synthetic small molecule (tsDMARD) that selectively inhibits all members of the Janus kinase family to varying degrees. At therapeutic doses, it exerts its effect mainly by inhibiting JAK3, and to a lesser extent JAK1, hence interrupting the JAK-STAT signaling pathway.

A

Tofacitinib (Xeljanz)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

This oral sedative drug, though banned due to teratogenic effects, is now currently used for treatment of Multiple Myeloma at initial diagnosis and for relapsed-refractory disease. Despite its toxicity, it is also now approved by the FDA for limited use as a potent immunoregulatory agent and to treat certain forms of leprosy (erythema nodosum leprosum).

A

Thalidomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

This is the immunomodulatory derivative of Thalidomide (IMiD) that is less toxic, less teratogenic, and effective for myelodysplastic syndrome with chromosome 5q31 deletion

A

Lenalidomide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Which group of immunosuppressants can cause profound myelosuppression, specifically thrombocytopenia?

A

Proliferation Signal Inhibitors (PSIs):
- Sirolimus
- Everolimus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Cell source (cells that release) IFN-γ

A

CD4 Th1, CD8 and NK cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Which Mabs bind and neutralize TNF-α and are important for ankylosing spondylitis?

A

TNF-α inhibitors particularly Infliximab and Adalimumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Which fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody blocks the binding of B. anthracis “protective” antigen to its cellular receptor?

A

Adalimumab

27
Q

Which alkylating cytotoxic agent can cause hemorrhagic cystitis?

A

Cyclophosphamide

28
Q

Which alkylating cytotoxic agent can cause pancytopenia when given in large doses?

A

Cyclophosphamide

29
Q

Cytokine that suppresses HIV replication and stimulates T-cell chemotaxis

A

IL-16

30
Q

Which fully human IgG2 kappa light chain monoclonal antibody binds to EGFR and is used in metastatic colorectal cancer?

A

Panitumumab

31
Q

Cell source (cells that release) IFN-α

A

Leukocytes

32
Q

Human-mouse chimeric Mab that targets EGRF and is used in head and neck squamous cell carcinoma and KRAS-negative, EGFR-positive metastatic colorectal cancer

A

Cetuximab

33
Q

Cytokine that stimulates eosinophil proliferation

A

IL-5

34
Q

Interleukin that in produced by hematopoietic stem cells

A

IL-3

35
Q

Mab that binds to CD38, which is over-expressed in myeloma cells

A

Daratumumab

36
Q

A ganglioside D2-binding Mab approved for pediatric patients with high-risk neuroblastoma in combination with GM-CSF, IL-2 and 13-cis-retinoic acid

A

Dinutuximab

37
Q

Which of the following is an acute phase protein that activates complement pathway for the opsonization of microbes?
A. Macrophage
B. Pentraxin
C. Collectin

A

B. Pentraxin (CRP)

38
Q

Cytokine that is also known as the T-cell growth factor

A

IL-2

39
Q

Cytokine that stimulates neutrophil chemotaxis

A

IL-8

40
Q

Mab targeting EGFR used for Squamous non-small cell lung CA in combination with gemcitabine and cisplatin

A

Necitumumab

41
Q

Treatment of relapsed multiple myeloma via antibody-dependent cell-mediated cytotoxicity (ADCC) after binding to SLAMF7 on myeloma cells

A

Elotuzumab

42
Q

Cell source (cells that releases) IFN-β

A

Fibroblasts

43
Q

Regulatory cytokine of Th2

A

IFN-γ

44
Q

Regulatory cytokine of Th1

A

IL-10

45
Q

Mab that blocks the cleavage of the complement protein C5

A

Eculizumab

46
Q

A prodrug of an inhibitor of pyrimidine synthesis that is approved only for RA

A

Leflunomide

47
Q

An active metabolite pyrimidine synthesis inhibitor that is approved for relapsing-remitting multiple sclerosis

A

Teriflumide

48
Q

Adenosine deaminase inhibitor that is used mainly as antineoplastic agent for lymphoid malignancies

A

Pentostatin

49
Q

Humanized IgG1 with a kappa chain that binds CD52 and is used for CLL that have failed with fludarabine therapy, and approved in the EU for RR-MS

A

Alemtuzumab

50
Q

Recombinant bi-specific trifunctional rat-mouse IgG hybrid mab that targets EpCAM and CD3

A

Catumaxomab

51
Q

Mab indicated for Glioblastoma multiform

A

Bevacizumab

52
Q

Cytotoxic agent that is useful in idiopathic thrombocytopenic purpura refractory to prednisone

A

Vincristine

53
Q

Profound AE of Pentostatin

A

lymphopenia

54
Q

Cytotoxic agent effectively used against acquired factor XIII antibodies and bleeding syndromes

A

Cyclophosphamide

55
Q

SEs of Muromonab-CD3 that resulted in its withdrawal from the market

A

Cytokine release syndrome and severe pulmonary edema

56
Q

Percent concentration of Rho (D) Ig solution of human IgG

A

15%

57
Q

After miscarriage, Rho (D) IgG treatment is recommended at ___ weeks of gestation

A

26-28 weeks

58
Q

Orphan drug for treating abdominal ascites in ovarian and gastric CA

A

Catumaxomab

59
Q

Human anti-mouse antibodies (HAMA) is generated in 4% of patients treated with:

A

Cetuximab

60
Q

Important SEs of Rituximab

A

Neutropenia and anemia

61
Q

The main adverse effect of Rituximab is countered by giving:

A

G-CSF for anemia and neutropenia

62
Q

This is a recombinant humanized monoclonal anti-body that targets all forms of VEGF-A. This antibody binds to and prevents VEGF-A from interacting with the target VEGF receptors. It is FDA approved as a first-line treatment for metastatic colorectal cancer in combination with any intravenous fluoropyrimidine-containing regimen and is now also approved in combination with chemotherapy for metastatic NSCLC and breast cancer.

A

Bevacizumab

63
Q

This is a monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy.

A

Tralokinumab